Literature DB >> 20617557

Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy.

Eliecer Coto1, Beatriz Tavira, Rafael Marín, Francisco Ortega, Carlos López-Larrea, Marta Ruiz-Ortega, Alberto Ortiz, Marta Díaz, Ana I Corao, Belén Alonso, Victoria Alvarez.   

Abstract

An intronic single nucleotide polymorphism (SNP) in the CYP3A5 gene (CYP3A5*3; SNP rs776746) affects RNA splicing and enzymatic activity. The CYP3A5*3 frequency increased with distance from the equator and natural selection has been proposed to explain the worldwide distribution of this allele. CYP3A activity has been related with the risk for hypertension in pregnancy, a major cause of morbidity and mortality among women, and CYP3A5*3 could reduce the risk for this disease in populations from regions with high sodium and water availability. The CYP3A5 genotype was related with blood pressure in the general population, but the effect on the risk for hypertension in pregnancy has not been evaluated.We compared the allele and genotype frequencies of three functional SNPs in the CYP3A5 (rs776746), CYP3A4 (rs2740574), and CYP21A2 (rs6471) genes between pregnant women who developed hypertension (n = 250) or who remained normotensive (control group, n = 250). In addition, we sequenced the full CYP3A5 coding sequence in 40 women from the two groups to determine whether some gene variants could explain the risk for hypertensive pregnancies in our population.Allele and genotype frequencies did not differ between hypertensive and normotensive women for the three CYP variants. We did not find CYP3A5 nucleotide changes that could explain a higher risk for hypertension in pregnancy. Our data suggests that the variation in CYP3A5, CYP3A4, and CYP21A2 did not contribute to the risk for hypertension in pregnancy in our population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20617557     DOI: 10.1016/j.bbrc.2010.06.003

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

Review 1.  CYP3A5 polymorphism, amlodipine and hypertension.

Authors:  Y-P Zhang; X-C Zuo; Z-J Huang; J-J Cai; J Wen; D D Duan; H Yuan
Journal:  J Hum Hypertens       Date:  2013-07-18       Impact factor: 3.012

2.  CYP3A5 as a candidate gene for hypertension: no support from an unselected indigenous West African population.

Authors:  D L Fisher; J Plange-Rhule; M Moreton; J B Eastwood; S M Kerry; F Micah; A Johnston; F P Cappuccio; I A M MacPhee
Journal:  J Hum Hypertens       Date:  2016-06-23       Impact factor: 3.012

3.  Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population.

Authors:  Mohammad Safiqul Islam; A G M Mostofa; Maizbha Uddin Ahmed; Muhammad Shahdaat Bin Sayeed; Md Rajib Hassan; Abul Hasnat
Journal:  Tumour Biol       Date:  2013-10-02

4.  Functional polymorphisms in CYP2C19 & CYP3A5 genes associated with decreased susceptibility for paediatric tuberculosis.

Authors:  Wei-Xing Feng; Fang Liu; Yi Gu; Wei-Wei Jiao; Lin Sun; Jing Xiao; Xi-Rong Wu; Qing Miao; Chen Shen; Dan Shen; Adong Shen
Journal:  Indian J Med Res       Date:  2012-05       Impact factor: 2.375

5.  Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine.

Authors:  Murielle Bochud; Michel Burnier; Idris Guessous
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-12

6.  Exploration of CYP21A2 and CYP17A1 polymorphisms and preeclampsia risk among Chinese Han population: a large-scale case-control study based on 5021 subjects.

Authors:  Bo Hou; Xuewen Jia; Ziwen Deng; Xin Liu; Huitang Liu; Haichu Yu; Shiguo Liu
Journal:  Hum Genomics       Date:  2020-09-25       Impact factor: 4.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.